Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Nov. 1, 2021:
Effective Dec. 1, 2021:
- Lysosomal Storage Disorders
- Synagis
- Neurotrophic Keratitis
- Urea Cycle Disorders
- Antihypertensive Medication
- Statin
- Bempedoic Acid
- Endari
- Ocaliva
- Oxbryta
- Vascepa
- Eysuvis
- Oral Anticoagulants
- Elagolix/Relugolix (formerly Elagolix)
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.
Institutional Providers
Professional Providers